Baxter International Inc. (NYSE:BAX) Shares Sold by Jaffetilchin Investment Partners LLC

Jaffetilchin Investment Partners LLC lowered its stake in shares of Baxter International Inc. (NYSE:BAX) by 12.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,512 shares of the medical instruments supplier’s stock after selling 8,243 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in Baxter International were worth $1,969,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. CoreFirst Bank & Trust purchased a new position in Baxter International during the 4th quarter worth approximately $26,000. Riverview Trust Co increased its holdings in shares of Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 933 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Baxter International by 48.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 656 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Baxter International by 61.2% during the 4th quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier’s stock worth $118,000 after purchasing an additional 1,541 shares during the period. Finally, Bruce G. Allen Investments LLC boosted its stake in Baxter International by 35.2% during the 1st quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 924 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Trading Down 0.2%

Shares of BAX opened at $30.53 on Friday. Baxter International Inc. has a twelve month low of $26.25 and a twelve month high of $40.49. The company has a current ratio of 2.02, a quick ratio of 1.40 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $15.67 billion, a P/E ratio of -27.76, a PEG ratio of 0.90 and a beta of 0.61. The firm’s 50-day moving average is $30.49 and its two-hundred day moving average is $31.20.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.14. The firm had revenue of $2.63 billion during the quarter, compared to the consensus estimate of $2.59 billion. Baxter International had a positive return on equity of 17.24% and a negative net margin of 4.71%. Baxter International’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.65 EPS. On average, research analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Friday, May 30th will be given a $0.17 dividend. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.68 annualized dividend and a dividend yield of 2.23%. Baxter International’s dividend payout ratio is presently -61.82%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company reduced their target price on shares of Baxter International from $36.00 to $33.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. Morgan Stanley dropped their price target on shares of Baxter International from $30.00 to $28.00 and set an “underweight” rating on the stock in a research note on Monday, May 5th. Barclays raised their price objective on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. Finally, Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research report on Sunday, June 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Baxter International has an average rating of “Moderate Buy” and an average target price of $37.25.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.